Published in Proc Natl Acad Sci U S A on September 08, 2005
Trial of Imatinib for Hospitalized Adults With COVID-19 | NCT04394416
Anti-inflammatory Agents: Present and Future. Cell (2010) 3.13
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest (2006) 2.10
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06
Imatinib attenuates skeletal muscle dystrophy in mdx mice. FASEB J (2009) 1.30
Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice. Diabetes (2009) 1.17
Polyketal copolymers: a new acid-sensitive delivery vehicle for treating acute inflammatory diseases. Bioconjug Chem (2008) 1.14
Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis. Toxicol Appl Pharmacol (2011) 0.92
Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches. Cells (2016) 0.91
An Extract of Antrodia camphorata Mycelia Attenuates the Progression of Nephritis in Systemic Lupus Erythematosus-Prone NZB/W F1 Mice. Evid Based Complement Alternat Med (2011) 0.89
Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis Therapy. Innov Clin Neurosci (2014) 0.86
Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells. Cancer Chemother Pharmacol (2010) 0.84
Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology (2014) 0.84
Prevention and treatment of Schistosoma mansoni-induced liver fibrosis in mice. Inflammopharmacology (2011) 0.83
Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome. Arterioscler Thromb Vasc Biol (2015) 0.82
Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol (2014) 0.82
Proteomic analysis of the hyaloid vascular system regression during ocular development. J Proteome Res (2008) 0.81
Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. Am J Physiol Lung Cell Mol Physiol (2015) 0.81
Protective effect of danhong injection on acute hepatic failure induced by lipopolysaccharide and d-galactosamine in mice. Evid Based Complement Alternat Med (2014) 0.81
Sunitinib enhances neuronal survival in vitro via NF-κB-mediated signaling and expression of cyclooxygenase-2 and inducible nitric oxide synthase. J Neuroinflammation (2013) 0.81
Acute Lung Injury Results from Innate Sensing of Viruses by an ER Stress Pathway. Cell Rep (2015) 0.80
PPARγ Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue. Diabetes (2016) 0.80
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Oncotarget (2015) 0.77
Galactose protects hepatocytes against TNF-α-induced apoptosis by promoting activation of the NF-κB signaling pathway in acute liver failure. Lab Invest (2015) 0.75
The inhibitory activity of cocoa phenolic extract against pro-inflammatory mediators secretion induced by lipopolysaccharide in RAW 264.7 cells. Springerplus (2016) 0.75
Effects of tripolyphosphate on cellular uptake and RNA interference efficiency of chitosan-based nanoparticles in Raw 264.7 macrophages. J Colloid Interface Sci (2016) 0.75
The protective effect of the natural compound hesperetin against fulminant hepatitis in vivo and in vitro. Br J Pharmacol (2016) 0.75
The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice. Physiol Rep (2015) 0.75
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res (1989) 22.73
NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol (1998) 21.48
Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol (2000) 20.70
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature (1997) 11.31
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med (1997) 10.67
The pathophysiology of tumor necrosis factors. Annu Rev Immunol (1992) 8.38
MAP kinases in the immune response. Annu Rev Immunol (2001) 7.62
Macrophage deactivation by interleukin 10. J Exp Med (1991) 6.94
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov (2002) 6.13
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med (1990) 4.90
Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J Exp Med (1987) 4.63
A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest (1992) 4.39
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res (1996) 3.77
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest (2004) 2.40
T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med (1994) 2.31
Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology (1996) 2.27
Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology (1995) 2.21
Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev (2003) 2.02
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood (2004) 2.01
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood (2003) 1.99
Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia (2004) 1.84
Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood (2004) 1.48
Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol (2000) 1.42
Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood (2004) 1.30
Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways. Clin Cancer Res (2005) 1.19
Inducible nitric oxide synthase is critical for immune-mediated liver injury in mice. J Clin Invest (2001) 1.12
Nramp1 functionality increases inducible nitric oxide synthase transcription via stimulation of IFN regulatory factor 1 expression. J Immunol (2003) 1.05
XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell (2008) 8.43
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res (2003) 3.44
Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun (2004) 3.21
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol (2007) 2.72
Autocrine formation of hepcidin induces iron retention in human monocytes. Blood (2007) 2.50
Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood (2009) 2.41
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood (2013) 2.34
Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways. Immunity (2011) 2.20
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
Endoscopic treatment of thoracic esophageal anastomotic leaks by using silicone-covered, self-expanding polyester stents. Gastrointest Endosc (2005) 2.07
Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med (2014) 2.07
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2004) 2.02
CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol (2005) 1.83
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford) (2011) 1.74
Duodenal HFE expression and hepcidin levels determine body iron homeostasis: modulation by genetic diversity and dietary iron availability. J Mol Med (Berl) (2004) 1.73
Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Nat Med (2007) 1.73
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis (2012) 1.71
ER stress transcription factor Xbp1 suppresses intestinal tumorigenesis and directs intestinal stem cells. J Exp Med (2013) 1.70
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica (2006) 1.66
TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol (2007) 1.63
Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood (2011) 1.63
IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol (2010) 1.52
Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy. Diabetes (2011) 1.52
Intestinal permeability--a new target for disease prevention and therapy. BMC Gastroenterol (2014) 1.52
The co-ordinated regulation of iron homeostasis in murine macrophages limits the availability of iron for intracellular Salmonella typhimurium. Cell Microbiol (2007) 1.51
Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol (2004) 1.50
Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis (2012) 1.49
The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. Cell Metab (2014) 1.47
EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol (2011) 1.46
Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res (2004) 1.46
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood (2013) 1.42
GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. Blood (2009) 1.37
Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut (2010) 1.30
Neopterin, a prognostic marker in human malignancies. Cancer Lett (2009) 1.28
Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol (2002) 1.27
Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol (2004) 1.26
Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr (2008) 1.25
Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology (2010) 1.23
Nitric oxide-mediated regulation of ferroportin-1 controls macrophage iron homeostasis and immune function in Salmonella infection. J Exp Med (2013) 1.22
High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol (2006) 1.18
Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun (2007) 1.16
A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease. Am J Gastroenterol (2010) 1.15
Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. Curr Pharm Des (2010) 1.08
Influence of visceral obesity and liver fat on vascular structure and function in obese subjects. Obesity (Silver Spring) (2009) 1.08
Inflammation, cytokines and insulin resistance: a clinical perspective. Arch Immunol Ther Exp (Warsz) (2013) 1.08
Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. J Hepatol (2005) 1.07
Role for hedgehog pathway in regulating growth and function of invariant NKT cells. Eur J Immunol (2009) 1.07
Interferon-alpha controls IL-17 expression in vitro and in vivo. Immunobiology (2008) 1.07
Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation (2007) 1.07
Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. Cancer Lett (2006) 1.07
Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med (2011) 1.06
Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer (2004) 1.05
Hypoxia up-regulates the angiogenic cytokine secretoneurin via an HIF-1alpha- and basic FGF-dependent pathway in muscle cells. FASEB J (2007) 1.05
IFN-gamma mediated pathways in patients with fatigue and chronic active Epstein Barr virus-infection. J Affect Disord (2007) 1.05
Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol (2005) 1.04
The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ Res (2010) 1.04
Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer (2012) 1.03
Lipocalin-2 ameliorates granulocyte functionality. Eur J Immunol (2012) 1.02
The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol (2005) 1.01
Kupffer cells modulate iron homeostasis in mice via regulation of hepcidin expression. J Mol Med (Berl) (2008) 1.01
The role of endocytic pathways in cellular uptake of plasma non-transferrin iron. Haematologica (2011) 1.00
Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer (2011) 1.00
The macrophage: a cellular factory at the interphase between iron and immunity for the control of infections. Biometals (2005) 0.99
Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo. Haematologica (2011) 0.99
Iron status in patients with chronic heart failure. Eur Heart J (2012) 0.99
Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn Pathol (2011) 0.99
Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol (2009) 0.98
Endothelial progenitor cells: a source for therapeutic vasculogenesis? J Cell Mol Med (2004) 0.97
RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol (2005) 0.97
Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab (2013) 0.96
Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. Am J Physiol Gastrointest Liver Physiol (2005) 0.96